IMAC Holdings Files S-1 Registration Statement

TL;DR

IMAC Holdings just filed an S-1, looks like they're gearing up to sell stock.

AI Summary

IMAC Holdings, Inc. filed an S-1 registration statement on June 13, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices in Franklin, Tennessee, operates in specialty outpatient facilities. This filing indicates a potential offering or significant corporate action by IMAC Holdings, Inc.

Why It Matters

This S-1 filing signals that IMAC Holdings, Inc. is preparing to offer securities, which could impact its capital structure and future growth prospects.

Risk Assessment

Risk Level: medium — An S-1 filing is a preliminary step for a public offering, which inherently carries market and execution risks.

Key Numbers

• 333-280184 — SEC File Number (Identifies the specific registration statement with the SEC.)
• 0001729944 — Central Index Key (Unique identifier for IMAC Holdings, Inc. in SEC filings.)

Key Players & Entities

• IMAC Holdings, Inc. (company) — Registrant
• June 13, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Franklin, Tennessee (location) — Principal Executive Offices
• Faith Zaslavsky (person) — Chief Executive Officer
• Kelley Drye & Warren LLP (company) — Legal Counsel

FAQ

Key Financial Figures

• $0.001 — ] shares of our common stock, par value $0.001 per share, or pre-funded warrant in lie
• $0.0001 — mmon stock and has an exercise price of $0.0001 per share. Each Pre-funded Warrant is b
• $2.51 — rted sale price of our common stock was $2.51 per share. We do not intend to list the
• $1,000,000 — from the Company up to an aggregate of $1,000,000 with an initial borrowing of $350,000 (
• $350,000 — $1,000,000 with an initial borrowing of $350,000 (the “Theralink Credit Agreement&
• $900,000 — ted in gross proceeds to the Company of $900,000. On April 30, 2024, the Company enter

Filing Documents

• forms-1.htm (S-1) — 563KB
• ex21-1.htm (EX-21.1) — 12KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 4KB
• ex107.htm (EX-FILING FEES) — 24KB
• forms-1_001.jpg (GRAPHIC) — 3KB
• forms-1_002.jpg (GRAPHIC) — 5KB
• 0001493152-24-023706.txt ( ) — 618KB

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 22 DESCRIPTION OF THE SECURITIES WE ARE OFFERING 28

UNDERWRITING

UNDERWRITING 29 LEGAL MATTERS 34 EXPERTS 34 WHERE YOU CAN FIND MORE INFORMATION 34 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 35 INDEMNIFICATION AGAINST LIABILITY UNDER THE SECURITIES ACT 35 i ABOUT THIS PROSPECTUS This prospectus is part of a Registration Statement on Form S-1 that we filed with the Securities and Exchange Commission (“SEC”). You should rely only on information contained in this prospectus filed with the Securities and Exchange Commission, or the SEC. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus is correct after the date of this prospectus. We have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell the securities registered hereby in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections of this prospectus entitled “Where You Can Find More Information.” This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful or in any state or other jurisdiction where the offer is not permitted. The information contained in this prosp

BUSINESS

BUSINESS OVERVIEW Until recently, we were a provider of movement and orthopedic therapies and minimally invasive procedures performed through our regenerative and rehabilitative medical treatments to improve the physical health of our patients at our chain of IMAC Regeneration Centers and BackSpace clinics which we owned or managed. Our outpatient medical clinics provided conservative, minimally invasive medical treatments to help patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. Our licensed healthcare professionals evaluated each patient and provided a custom treatment plan that integrated traditional medical procedures and innovative regenerative medicine procedures in combination with physical medicine. We did not use or offer opioid-based prescriptions as part of our treatment options in order to help our patients avoid the dangers of opioid abuse and addiction. As of December 31, 2023, we sold or discontinued patient care at all our locations including The BackSpace LLC. In May 2024, we acquired the business, consisting of the material assets and rights, of Theralink Technologies, Inc. (“Theralink”). The business is a precision medicine company with a nationally CLIA-certified , CAP-accredited and NY CLEP certified laboratory in Golden, Colorado. Our product is Theralink’s unique and patented Reverse Phase Protein Array (RPPA) technology platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Because protein signaling is responsible for the development and progression of cancer, nearly all FDA-approved cancer therapeutics target proteins, not genes. The Theralink® RPPA technology can reveal the protein drug target(s) that are essentially turned “on” in a patient’s cancer and may help support the most effective treatment plan to turn those proteins “off”. The

View Full Filing

View this S-1 filing on SEC EDGAR